effector

CK-666 is a cell-permeable inhibitor of the actin-related protein Arp2/3 complex, binding to and stabilizing its inactive state, thereby preventing the movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) configuration.

BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).

Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.Zolbetuximab is used in the study of gastrointestinal adenocarcinomas and pancreatic tumors.

Psora 4 (5-(4-Phenylbutoxy)psoralen) is a selective and potent Kv1.3 blocker, a caloric restriction mimetic with immunosuppressive activity that enhances neural progenitor cell differentiation and maturation.

3-Hydroxykynurenamine, also known as 3-Hydroxy-L-kynurenamine or 3-HKA, is a biogenic amine produced via an alternative pathway of tryptophan metabolism. In vitro, 3-HKA has an anti-inflammatory profile by inhibiting the IFN-γ mediated STAT1/NF-κΒ pathway in both mouse and human dendritic cells (DCs) with a consequent decrease in the release of pro-inflammatory chemokines and cytokines, most notably TNF, IL-6, and IL12p70. 3-HKA has protective effects in an experimental mouse model of psoriasis by decreasing skin thickness, erythema, scaling and fissuring, reducing TNF, IL-1β, IFN-γ, and IL-17 production, and inhibiting generation of effector CD8+ T cells. Similarly, in a mouse model of nephrotoxic nephritis, besides reducing inflammatory cytokines, 3-HKA improves proteinuria and serum urea nitrogen, overall ameliorating immune-mediated glomerulonephritis and renal dysfunction.This compound is unstable in powder form and other related salt forms are recommended.

Acetylcholine bromide is the bromide salt of acetylcholine. It is an neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central ner

Acetylcholine iodide (Acetylcolina) is a neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1].

Evunzekibart is a human monoclonal antibody and a Fcγ receptor-dependent 4-1BB (CD137/TNFRSF9) agonist. Evunzekibart exerts potent antitumor immune activity by selectively activating effector T cells and NK cells in the tumor microenvironment. Evunzekibart is being investigated as a monotherapy or in combination with anti-PD-1/PD-L1 agents for the treatment of advanced solid tumors.

A-9758 is a RORγ ligand and selective RORγt inverse agonist (IC50: 5 nM) that effectively suppresses IL-17A release, Th17 differentiation, and Th17 effector function, significantly attenuating IL-23 driven psoriasiform dermatitis.

AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene.

JI051 is an antitumor agent that interacts with the cancer-associated protein chaperone prohibitin 2 (PHB2) to induce cell cycle arrest by inhibiting the transcription of the Notch downstream effector gene, Hes1, and inhibits the proliferation of HEK293 cells and pancreatic cancer cells.

CA-170 is an orally bioavailable dual inhibitor of VISTA and PD-L1 that selectively restores T-cell proliferation and effector function suppressed by immune checkpoint signaling, while demonstrating minimal off-target activity across a broad receptor and enzyme panel, making CA-170 a valuable compound for immuno-oncology research and immune checkpoint modulation studies.

PRN694 shows extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. PRN694 is an irreversible, highly selective, and effective covalent interleukin-2-inducible T-cell kinase (ITK) and resting ly

6BrW is an analog of tryptophan effector.

L-5-BromoTryptophan (5-BrW) is an analog of the tryptophan (Trp) effector and inhibits the gelation of hemoglobin S.

AM-001, a non-competitive inhibitor of Epac1, effectively blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells, and is commonly used in heart disease-related research.

PF-07265028 is a highly potent and selective small-molecule inhibitor of hematopoietic progenitor cell kinase 1 (HPK1/MAP4K1). By blocking HPK1-mediated signal transduction, PF-07265028 enhances T-cell receptor-associated signaling, thereby lifting immune suppression and promoting antitumor immune responses. PF-07265028 exhibits significant activity at the cellular level (e.g., inhibition of pSLP76, IC₅₀ approximately 17 nM). PF-07265028 is suitable for use in cancer research.

Y-30141 is closely related to the commonly used ROCK inhibitor, Y-27632. This compound inhibits the kinase activity of both ROCK-I and ROCK-II by competitively binding to the catalytic site, showing 20 to 30 times greater affinity for ROCK kinases compared to other Rho effector kinases. Furthermore, the inhibition mechanism and action profile of Y-30141 have also been investigated.

Lipid C2 is an ionizable cationic lipid utilized in the formation of lipid nanoparticles (LNP) for the delivery of mRNA in vivo. LNPs containing Lipid C2 and encapsulating mRNA reporter genes specifically accumulate in the liver and spleen of mice, while avoiding the heart, lungs, and kidneys. Additionally, LNPs with Lipid C2 that encapsulate mRNA encoding Epstein-Barr virus (EBV) protein Latent Membrane Protein 2 (LMP-2), when combined with anti-programmed cell death protein 1 (PD-1) antibodies, have been shown to reduce tumor size, reverse T cell exhaustion, increase the percentage of CD3+CD8+ central T cells and CD3+CD8+ effector memory T cells in the spleen, and decrease the percentage of CD3+T cells expressing Pd-1 in a CT26 mouse model of EBV-infected colon cancer.

Phenylacetyl Coenzyme A (Phenylacetyl Coenzyme A) tetrasodium serves as an effector molecule for the TetR family transcription repressor protein PaaR. It alters the conformation of PaaR, facilitating its dissociation from DNA and initiating transcription. This compound holds potential for use in the study of microbial metabolism.

SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.

HLDA-212 (Compound 43) is a bifunctional small molecule designed to target HaloTag-tagged protein (target protein, TP) and Aurora kinase A/B (AURKA/B, effector protein, EP). By binding TP and EP, it forms a stable ternary complex (TP:RIPTAC:EP) that inhibits the cell survival functions of EP, inducing apoptosis in cancer cells expressing TP. In 293_HFL cells, HLDA-212 demonstrates antiproliferative activity with a GI50 of 0.011 μM. This compound holds promise for treating cancers with high TP expression, such as prostate cancer and hematological malignancies.

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for prostate cancer, effectively suppressing downstream effector molecules through the inhibition of SOS1 and EGFR. It induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. In prostate cancer cells PC-3, it demonstrates significant antitumor activity with an IC50 of 0.45±0.03 μM.